AMS stock touches 52-week low at $2.5 amid market challenges

American Shared Hospital Services ( AMS (VIE:AMS2)) stock has hit a 52-week low, dropping to $2.5 as the company faces a turbulent market environment. According to InvestingPro data, the company’s current valuation shows signs of being undervalued, with a P/B ratio of 0.65 and an EV/EBITDA multiple of 4.57. This latest price level reflects a significant downturn from the previous year, with AMS experiencing a 1-year change of -25.29%. Investors are closely monitoring the stock as it navigates through the healthcare sector’s current headwinds, which have contributed to its decline over the past year. The company, known for providing technology solutions to healthcare providers, is now at a critical juncture as it attempts to regain its footing and reassure shareholders of its long-term value. While the company maintains profitability with a 48% gross margin and revenue growth of 35% in the last twelve months, InvestingPro analysis reveals several additional key metrics and insights available to subscribers, including detailed Fair Value analysis and comprehensive financial health scores.

In other recent news, American Shared Hospital Services (AMS) reported a net loss of $625,000 for the first quarter of 2025, translating to earnings per share of -$0.10. Despite this loss, the company’s revenue grew by 17% year-over-year, reaching $6.1 million, primarily driven by a 224% increase in revenue from direct patient services. However, revenue from equipment leasing experienced a decline, contributing to investor concerns. In a move to expand its international presence, AMS opened new centers in Latin America, which aligns with its long-term growth strategy. The company has also been focusing on its Rhode Island and Mexico locations, with expectations of improved performance in the latter half of the year. Additionally, AMS announced plans to build a proton beam radiation therapy center in Rhode Island, marking a significant growth opportunity. Analysts have noted the company’s mixed results, with firms like Zacks showing interest in future regulatory impacts on reimbursement policies. AMS remains optimistic about its growth potential, citing strong cost controls and strategic initiatives as key drivers.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.